Table 5.
Characteristics | Odds ratio | 95% CI | P value | Adjusted odds ratio | 95% CI | P value |
---|---|---|---|---|---|---|
Male gender | 0.76 | 0.44–1.33 | 0.336 | 0.93 | 0.41–2.12 | 0.855 |
Stavudine-based ART regimen | 0.58 | 0.33–1.01 | 0.055 | 0.50 | 0.27–0.93 | 0.028 |
Age | 1.32* | 1.14–1.54 | <0.001 | 1.31 | 1.11–1.56 | 0.002 |
ART duration | 1.09 | 0.82–1.46 | 0.550 | |||
Initial CD4 counts per 50 cells/μL increase | 0.94 | 0.80–1.11 | 0.463 | |||
ART start body weight | 1.00 | 0.97–1.03 | 0.95 | |||
Peak body weight >65 kgs | 1.00 | 0.92–1.09 | 0.957 | |||
Enrolment BMI <24 | 1.00 | 1.00–1.02 | 0.213 | |||
Systolic blood pressure >150 mm/Hg | 1.02 | 1.00– 1.03 | 0.05 | 1.01 | 0.90–1.03 | 0.146 |
Enrolment CD4 count >200 cells/μL | 1.06 | 0.55–2.05 | 0.86 | |||
Abnormal waist to hip ratio+ | 1.97 | 1.01–3.84 | 0.046 | 1.73 | 0.67–4.46 | 0.255 |
Family history of hypertension | 0.99 | 0.57–1.73 | 0.972 | |||
Family history of diabetes mellitus | 1.71 | 0.91–3.22 | 0.095 | 2.18 | 1.10–4.34 | 0.026 |
Lipodystrophy | 0.98 | 0.56–1.89 | 0.946 | |||
WHO stage III and IV | 1.00 | 0.54–1.85 | 0.991 |
CI: confidence interval; ART: antiretroviral treatment; BMI: body mass index; WHO: World Health Organization.
+WHR defined abnormal if >0.94 for males and >0.8 for females.
*Denote that age as a variable was supposed to be interpreted as a 5-year increase as interpreted in the text.